MGF
Fat LossIGF-1 splice variant / researchExperimental
Mechano growth factor is the IGF-1Ec splice variant induced by muscle loading. Research MGF peptides are not an FDA drug. WADA S2.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Research-dependent
- Last updated
- 8/23/2026
- Targets
- IGF-1 receptorSatellite cells (proposed)
Overview
Mechano growth factor is the IGF-1Ec splice variant induced by muscle loading. Research MGF peptides are not an FDA drug. WADA S2.
Protocol
- Dosage Range
- Not established as a drug
- Frequency
- Research-dependent
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Alternative splicing of IGF-1 yields a C-terminal E-peptide unique to MGF, implicated in satellite-cell activation after mechanical stress.
Targets
IGF-1 receptorSatellite cells (proposed)
Studies
- MGF review— Journal/year not available
Benefits
Load-adaptation research
Potential Side Effects
- Unknown human AE profile
References
- PMID 16581882External link · Year —
- WADA Prohibited List 2026External link · Year —